Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome
Setmelanotide treatment is associated with improvement of MASLD independent of BMI reduction as well as increased glomerular filtration rate in BBS.
Authors
- Wolfgang Galetzka
- Eva‐Maria Huessler (ORCID: https://orcid.org/0000-0002-8144-5428)
- Lars Dinkelbach (ORCID: https://orcid.org/0000-0002-5617-4451)
- Cordula Kiewert
- Thomas Scherer (ORCID: https://orcid.org/0000-0003-4980-706X)
- Lars Pape (ORCID: https://orcid.org/0000-0002-3635-6418)
- Metin Cetiner (ORCID: https://orcid.org/0000-0002-0918-9204)
- Ilja Finkelberg
- Anja Gäckler (ORCID: https://orcid.org/0000-0002-3630-4386)
- Arend Bökenkamp (ORCID: https://orcid.org/0000-0002-3492-2252)
- Tom Hühne
- Pia Brensing (ORCID: https://orcid.org/0009-0005-7965-8888)
- Johannes Jaegers
- Ioanna Maria Polichronidou
Institutions
- Institut für Medizinische Informatik, Biometrie und Epidemiologie (DE)
- Emma Kinderziekenhuis (NL)
- Essen University Hospital (DE)
- Amsterdam University Medical Centers (NL)
- University of Duisburg-Essen (DE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1210/clinem/dgaf483
- Citations
- 3
- Primary Topic
- Genetic and Kidney Cyst Diseases
- Type
- article
- Field-Weighted Citation Impact
- 5.45
Funders
- Sanofi
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Ablynx
- Bundesministerium für Bildung und Forschung